# Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM

Source: https://onco.cc/trials/nct07084896/  
OnCo record `nct07084896` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Belantamab mafodotin, Nirogacestat in multiple myeloma, run by GlaxoSmithKline, active and no longer recruiting.

## Summary

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM is a phase 1/2 interventional study registered as NCT07084896 by GlaxoSmithKline, with 106 participants enrolled, started 2020-06-08 and due to reach its primary completion in 2025-04-17. Interventions recorded: Belantamab mafodotin, Nirogacestat. Conditions listed: Multiple Myeloma. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: ctgov-ingest
- Registry id: NCT07084896
- Phase: 1/2
- Setting: A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5 - Sub-study 3 - Belantamab Mafodotin and Nirogacestat in Combination
- Sponsor: GlaxoSmithKline
- Enrolled: 106
- Outcomes: CE Phase: Overall Response Rate (ORR): CE Phase: 0.95mg/kg Belantamab Mafodotin Q3W + Nirogacestat 29% vs CE Phase: 2.5mg/kg Belantamab Mafodotin Q3W 38%; CE Phase: Progression-free Survival (PFS): CE Phase: 0.95mg/kg Belantamab Mafodotin Q3W + Nirogacestat 3.5 months vs CE Phase: 2.5mg/kg Belantamab Mafodotin Q3W 9.6 months

## Sources

- ClinicalTrials.gov NCT07084896: https://clinicaltrials.gov/study/NCT07084896

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Gamma-secretase inhibitors](https://onco.cc/technologies/gamma-secretase-inhibitors/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Belantamab mafodotin](https://onco.cc/drugs/belantamab-mafodotin/), [Nirogacestat](https://onco.cc/drugs/nirogacestat/)
- companies: [GSK](https://onco.cc/companies/gsk/)

---
JSON: https://onco.cc/api/v1/entities/nct07084896.json